www.impactjournals.com/oncotarget/ Oncotarget, Supplementary Materials 2017 High expression of dedicator of cytokinesis 1 (DOCK1) confers poor prognosis in acute myeloid leukemia SUPPLEMENTARY MATERIALS Supplementary Figure 1: Kaplan Meier survival curves for AML patients stratified by DOCK2 expression levels. Overall survival of AML patients with different DOCK2 levels in all the three independent cohorts (NTUH, TCGA and GSEA12417-GPL 96). Red line: higher DOCK1 expression; blue line: lower DOCK1 expression.
10
Embed
High expression of dedicator of cytokinesis 1 (DOCK1) …€¦ · · 2017-10-25DNMT3A mutation 1.350 0.875 2.083 0.175 ... YES1 1535 1.912 High DOCK1 0.6639 ... Microsoft Word -
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
High expression of dedicator of cytokinesis 1 (DOCK1) confers poor prognosis in acute myeloid leukemia
SUPPLEMENTARY MATERIALS
Supplementary Figure 1: Kaplan Meier survival curves for AML patients stratified by DOCK2 expression levels. Overall survival of AML patients with different DOCK2 levels in all the three independent cohorts (NTUH, TCGA and GSEA12417-GPL 96). Red line: higher DOCK1 expression; blue line: lower DOCK1 expression.
Supplementary Table 3: Multivariate analysis (Cox regression) on the disease free survival*
Variables
Diease free survival
HR 95% CIP value
Lower Upper
Total cohort (n=227)
Age 1.013 1.001 1.025 0.033
WBC 1.000 1.000 1.000 0.142
Unfavorable cytogenetics 2.426 1.390 4.235 0.002
FLT3-ITD 1.155 0.751 1.777 0.512
CEBPAdouble mutation 0.765 0.390 1.501 0.436
RUNX1 mutation 1.399 0.826 2.370 0.212
DNMT3A mutation 1.350 0.875 2.083 0.175
MLL-PTD 1.372 0.624 3.014 0.432
TP53 mutation 2.237 0.832 6.015 0.111
DOCK1 higher expression 1.659 1.262 2.182 <0.001
*The model was generated from a stepwise Cox regression model that included age, WBC, unfavorable cytogenetics, gene mutations of FLT3, CEBPA, RUNX1, DNTM3A, MLL, TP53 and expression level of DOCK1.HR, hazard ratio; CI, confidence interval; WBC, white blood cell count.
Supplementary Table 4: Association of DOCK1 expression levels with cytogenetic abnormalities
Variables TotalHigher DOCK1
expressionLower DOCK1
expressionP
Karyotype † 347 174 173 <0.001
Favorable 60 8 (13.3%) 52 (86.7%) <0.001
Intermediate 223 125 (56.1%) 98 (43.9%) 0.003
Unfavorable 49 29 (59.2%) 20 (40.8%) 0.172
Unknown 15 12 (80%) 3 (20%) 0.018
Normal 167 92 (55.1%) 75 (44.9%) 0.021
t(8;21) 24 1 (4.2%) 23 (95.8%) <0.001
t(15;17) 27 1 (3.7%) 26 (96.3%) <0.001
inv(16) 9 6 (66.7%) 3 (33.3%) 0.277†Favorable, t(15;17), t(8;21), inv (16) or t(16;16); unfavorable, inv(3), t(3;3), t(6;9), t(v;11)(v;q23), -7, -5, del(5q), abnl(17p), complex abnormalities‡; Intermediate, t(9;11), normal karyotype and other abnormalities not classified as favorable or adverse.‡ Complex karyotype is defined as three or more chromosome abnormalitiesin the absence of one of the WHO designated recurring translocations or inversions: t(8;21), inv(16) or t(16;16), t(15;17), t(9;11), t(v;11)(v;q23), t(6;9), inv(3) or t(3;3).